Phase 1b/2 placebo-controlled trial of ABBV-916 in 106 patients with early Alzheimer's disease: amyloid fell over 24 weeks at doses ≥300 mg; most adverse events were non-serious ARIA, and the top dose was cut. The programme stopped for business reasons.
RCTn = 106
Lynch et al. A randomized phase 1b/2 trial of ABBV-916 in adults with early Alzheimer's disease